TW202142254A - 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子 - Google Patents
用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子 Download PDFInfo
- Publication number
- TW202142254A TW202142254A TW110102010A TW110102010A TW202142254A TW 202142254 A TW202142254 A TW 202142254A TW 110102010 A TW110102010 A TW 110102010A TW 110102010 A TW110102010 A TW 110102010A TW 202142254 A TW202142254 A TW 202142254A
- Authority
- TW
- Taiwan
- Prior art keywords
- mydgf
- heart failure
- fibrosis
- hypertrophy
- protein
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20153008 | 2020-01-21 | ||
| EP20153008.6 | 2020-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202142254A true TW202142254A (zh) | 2021-11-16 |
Family
ID=69187588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110102010A TW202142254A (zh) | 2020-01-21 | 2021-01-19 | 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230059560A1 (https=) |
| EP (1) | EP4093750A1 (https=) |
| JP (1) | JP7777532B2 (https=) |
| KR (1) | KR20220131262A (https=) |
| CN (1) | CN115698048A (https=) |
| AU (1) | AU2021211874A1 (https=) |
| BR (1) | BR112022014272A2 (https=) |
| CA (2) | CA3164500A1 (https=) |
| MX (1) | MX2022008727A (https=) |
| PH (1) | PH12022551792A1 (https=) |
| TW (1) | TW202142254A (https=) |
| WO (1) | WO2021148411A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11980654B2 (en) | 2020-09-22 | 2024-05-14 | Wisconsin Alumni Research Foundation | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor |
| JP2024501821A (ja) | 2020-12-23 | 2024-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓組織細胞に対する特異性を有するウイルスカプシドタンパク質 |
| CN115820829B (zh) * | 2022-03-22 | 2026-04-17 | 中国人民解放军军事科学院军事医学研究院 | Mydgf在防治记忆损伤及其相关疾病中的应用 |
| CA3258215A1 (en) | 2022-06-03 | 2023-12-07 | Boehringer Ingelheim International Gmbh | RECOMBINANT EXPRESSION OF THE MYELOID-DERIVED GROWTH FACTOR |
| CN120112304A (zh) | 2022-09-08 | 2025-06-06 | 勃林格殷格翰国际有限公司 | 用于治疗心源性休克的髓源性生长因子 |
| EP4480490A1 (en) * | 2023-06-23 | 2024-12-25 | Medizinische Hochschule Hannover | Brick1 for use in treating myocardial diseases |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| WO2025120204A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| WO1997047358A1 (en) | 1996-06-11 | 1997-12-18 | Merck & Co., Inc. | Synthetic hepatitis c genes |
| JP2001506484A (ja) | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| AU4220797A (en) * | 1996-09-13 | 1998-04-02 | Protegene Inc. | Human proteins having secretory signal sequences and DNAs encoding these prot eins |
| EP1578367A4 (en) | 2002-11-01 | 2012-05-02 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| EP3747457A3 (en) | 2013-01-17 | 2021-03-03 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| KR20250133994A (ko) * | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| WO2020176732A1 (en) * | 2019-02-27 | 2020-09-03 | Icahn School Of Medicine At Mount Sinai | TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY |
-
2021
- 2021-01-19 MX MX2022008727A patent/MX2022008727A/es unknown
- 2021-01-19 EP EP21701283.0A patent/EP4093750A1/en active Pending
- 2021-01-19 TW TW110102010A patent/TW202142254A/zh unknown
- 2021-01-19 CA CA3164500A patent/CA3164500A1/en active Pending
- 2021-01-19 BR BR112022014272A patent/BR112022014272A2/pt unknown
- 2021-01-19 CA CA3223879A patent/CA3223879A1/en active Pending
- 2021-01-19 CN CN202180022864.1A patent/CN115698048A/zh active Pending
- 2021-01-19 WO PCT/EP2021/051079 patent/WO2021148411A1/en not_active Ceased
- 2021-01-19 US US17/759,056 patent/US20230059560A1/en active Pending
- 2021-01-19 KR KR1020227027546A patent/KR20220131262A/ko active Pending
- 2021-01-19 AU AU2021211874A patent/AU2021211874A1/en active Pending
- 2021-01-19 PH PH1/2022/551792A patent/PH12022551792A1/en unknown
- 2021-01-19 JP JP2022544144A patent/JP7777532B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023511358A (ja) | 2023-03-17 |
| EP4093750A1 (en) | 2022-11-30 |
| CA3164500A1 (en) | 2021-07-29 |
| WO2021148411A1 (en) | 2021-07-29 |
| MX2022008727A (es) | 2022-10-07 |
| JP7777532B2 (ja) | 2025-11-28 |
| BR112022014272A2 (pt) | 2022-09-20 |
| AU2021211874A1 (en) | 2022-08-25 |
| CA3223879A1 (en) | 2021-07-29 |
| CN115698048A (zh) | 2023-02-03 |
| PH12022551792A1 (en) | 2023-09-18 |
| KR20220131262A (ko) | 2022-09-27 |
| US20230059560A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202142254A (zh) | 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子 | |
| JP7305543B2 (ja) | 組織特異的Ｗｎｔシグナル増強分子およびその使用 | |
| JP2025143268A (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP2005139121A (ja) | ｐ３８／ＪＴＶ−１を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法 | |
| JP6401292B2 (ja) | 抗ｎｍｅ抗体 | |
| JP6605467B2 (ja) | Ｖｅｇｆ−ｃおよびｃｃｂｅ１の治療的使用 | |
| CN102112149A (zh) | Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用 | |
| CN113301914B (zh) | 用于治疗和预防纤维化的组合物和方法 | |
| JP2009019032A (ja) | 血管形成及び心臓血管新生の促進又は阻害 | |
| KR20150140686A (ko) | 신증후군 및 관련 병태의 치료 방법 | |
| US11944671B2 (en) | Hippo pathway deficiency reverses systolic heart failure post-infarction | |
| TW201200151A (en) | Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells | |
| TW202421648A (zh) | 用於治療心因性休克的骨髓衍生性生長因子(一) | |
| CN116925205A (zh) | 激活Hippo信号通路的多肽及其用途 | |
| EA053022B1 (ru) | Фактор роста миелоидного происхождения для применения при лечении или профилактике фиброза, гипертрофии или сердечной недостаточности | |
| Yang et al. | Cardiac fibroblasts-specific USP7 drives post-infarction cardiac fibrosis by deubiquitinating Krüppel-like factor 7 to promote myofibroblast activation | |
| HK40088501A (zh) | 用於治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 | |
| WO2026092346A1 (zh) | Kif13b基因在药物上的应用 | |
| HK40029335A (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| JP2015525770A (ja) | 血管再構築のためのＮｋｘ２．５阻害剤 |